Search Videos by Topic or Participant
Browse by Series:

Prostate Cancer Management: Introduction and Overview

Panelists: Raoul S. Concepcion, MD, Urology Associates, PC; Steve Dobbs, Urologic Associates of Oklahoma; Bryan A. Mehlhaff, MD, Oregon Urology Institute;
Published Online: Wednesday, Dec 12, 2012
For High-Definition, Click
In the first installment of the series, the moderator, Raoul S. Concepcion, MD, provides an overview of the prostate cancer treatment continuum and introduces the panel, which includes: Steve Dobbs, Bryan A. Mehlhaff, MD, Neal D. Shore, MD, and Daniel R. Saltzstein, MD.

This panel discussion seeks to address a range of challenges facing the treatment of men with prostate cancer. Panelist will discuss a range of topics, from data on the many new treatments for prostate cancer to reimbursement and other practice management issues.

Concepcion provides a summary of the current treatment continuum for men with prostate cancer. He explains that androgen deprivation therapy (ADT) is still used as the early treatment for advancing prostate cancer in patients who have failed definitive therapy. In general, ADT lowers androgen levels and stops the growth of prostate cancer cells. However, patients will eventually fail ADT, which manifests in a raise in PSA levels. Following the failure of hormonal therapy, urologists have traditionally referred patients to medical oncologists.
Slider Left
Slider Right
For High-Definition, Click
In the first installment of the series, the moderator, Raoul S. Concepcion, MD, provides an overview of the prostate cancer treatment continuum and introduces the panel, which includes: Steve Dobbs, Bryan A. Mehlhaff, MD, Neal D. Shore, MD, and Daniel R. Saltzstein, MD.

This panel discussion seeks to address a range of challenges facing the treatment of men with prostate cancer. Panelist will discuss a range of topics, from data on the many new treatments for prostate cancer to reimbursement and other practice management issues.

Concepcion provides a summary of the current treatment continuum for men with prostate cancer. He explains that androgen deprivation therapy (ADT) is still used as the early treatment for advancing prostate cancer in patients who have failed definitive therapy. In general, ADT lowers androgen levels and stops the growth of prostate cancer cells. However, patients will eventually fail ADT, which manifests in a raise in PSA levels. Following the failure of hormonal therapy, urologists have traditionally referred patients to medical oncologists.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Genitourinary CancersJul 28, 20171.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication